Mohmed K Anwer is a notable inventor based in Foster City, CA (US). He has made significant contributions to the field of pharmacology, particularly in the development of viral fusion inhibitor peptides. With a total of 5 patents to his name, Anwer's work focuses on enhancing the pharmacokinetic properties of therapeutic agents.

Latest Patents

Anwer's latest patents include groundbreaking inventions such as DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating AIDS. This invention relates to enhancer peptide sequences derived from various retroviral envelope (gp41) protein sequences. These sequences enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The discovery that hybrid polypeptides comprising these enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties, such as increased half-life, is a significant advancement. Furthermore, the invention outlines methods for enhancing the pharmacokinetic properties of core polypeptides through the linkage of enhancer peptide sequences.

Career Highlights

Anwer is currently associated with Trimeris, Inc., where he continues to innovate in the field of pharmacology. His work has been instrumental in developing therapeutic agents that can be used as prophylactic reagents.

Collaborations

Anwer collaborates with various professionals in his field, including his coworker Shawn Barney. Their combined expertise contributes to the advancement of research in viral fusion inhibitors.

Conclusion

Mohmed K Anwer's contributions to the field of pharmacology through his innovative patents highlight his role as a leading inventor in the development of viral fusion inhibitor peptides. His work continues to pave the way for new therapeutic solutions.